LOMN Best Practices by Specialty

What a Letter of Medical Necessity Actually Does

The Letter of Medical Necessity (LOMN) is the narrative bridge between clinical reality and payer adjudication criteria. Payer reviewers — often nurses or medical directors working with clinical policy bulletins (CPBs) that define medical necessity criteria in highly specific terms — use the LOMN to confirm that a patient's situation meets the threshold for authorization. A strong LOMN does not tell the reviewer that the procedure is a good idea; it demonstrates, point by point, that the patient meets the payer's own stated criteria.

This distinction matters enormously. Providers who write LOMNs from the perspective of "here is why I think this patient needs this procedure" are answering the wrong question. Payer reviewers do not doubt the provider's clinical judgment — they are checking boxes against a policy document. The LOMN must be written to speak the payer's language: meet the diagnosis criteria, confirm the required prior treatments were completed, document the functional impact, and project the clinical outcome with and without the requested treatment.

LOMNs are required most commonly for: high-cost DME (custom orthotics, power wheelchairs, CPAP), surgical procedures with significant payer scrutiny (lumbar fusion, total joint replacement, bariatric surgery), biologic medications in rheumatology, dermatology, gastroenterology, and oncology, neurostimulation and neuromodulation devices (DBS, spinal cord stimulator), and advanced diagnostic imaging in some managed care plans.

A poorly written LOMN — vague, generic, or missing required elements — can cause denial even when the clinical need is unambiguous. The appeal rate for LOMN-related denials is high (55–65% overturn with a strengthened LOMN), but the delay and administrative cost of an appeal cycle is significant. Building strong LOMNs at the point of initial submission is always preferable to correcting them after a denial.

The Six Elements of a Strong LOMN

Regardless of specialty, every strong LOMN should contain six structural elements. Missing any one of them introduces denial risk.

1. Diagnosis with specificity: The LOMN must open with the patient's diagnosis stated in clinical and ICD-10 terms. "Low back pain" is not sufficient. "L4-L5 disc herniation with left-sided L5 radiculopathy (ICD-10: M51.16, M54.42) confirmed on MRI dated [date] showing [finding]" gives the reviewer everything needed to match the request against the CPB.

2. Failed conservative management with dates: Every LOMN for a surgical or advanced treatment should document what was tried before this treatment, how long it was tried, and how the patient responded. Dates are mandatory — "patient has had physical therapy" without start and end dates is routinely rejected. Format: "Patient completed 8 weeks of formal physical therapy (12 sessions, [clinic name], [dates]), with final outcome measures documenting continued [pain score] and [functional limitation] despite adherence to the full course."

3. Clinical rationale: This is the section where the provider explains the clinical logic connecting the diagnosis, the failed conservative treatment, and the requested procedure. It should reference relevant clinical guidelines (ACS, NASS, ACR, ASCO as applicable), cite objective findings, and use the patient's own data — not generic population data.

4. Functional impact: Payers increasingly require documentation of how the condition affects the patient's daily life — ability to work, perform ADLs, ambulate, maintain independence. Functional impact statements that reference standardized assessment tools (Oswestry Disability Index, KOOS, HAQ, PHQ-9) are stronger than narrative descriptions alone.

5. Prognosis with and without treatment: The LOMN should explicitly state what the patient's prognosis is if the requested treatment is not authorized. This is the medical necessity argument at its core: if denial of authorization leads to predictable deterioration, disability, or higher-cost intervention later, stating that directly addresses the payer's total cost of care calculus.

6. Provider credentials and contact: The LOMN must be signed by the requesting provider, include their NPI, specialty, and direct contact information for the peer-to-peer call that may follow denial.

Spine Surgery LOMN: ACDF Example

Anterior Cervical Discectomy and Fusion (ACDF) is one of the highest-denial-risk procedures in spine surgery authorization, with initial denial rates of 20–30% at major commercial payers including Aetna, UnitedHealthcare, and BCBS for cases where the LOMN is incomplete. Most payers require documentation of: (1) cervical radiculopathy or myelopathy confirmed on imaging, (2) failure of at least 6 weeks of conservative care unless neurological emergency, and (3) functional disability severity.

A strong ACDF LOMN follows this structure:

Diagnosis paragraph: Identify the specific disc level(s) involved with ICD-10 codes. Example: "[Patient] presents with C5-C6 disc herniation (M50.12) with right C6 radiculopathy (M54.12) confirmed on MRI cervical spine dated [date], demonstrating [specific finding: e.g., right paracentral disc protrusion with moderate foraminal narrowing and cord contact]."

Conservative management paragraph: "Patient completed 10 weeks of structured physical therapy (dates), received two cervical epidural steroid injections at C5-C6 (dates and response — 'initial 30% improvement lasting 6 weeks, then return to baseline pain'), and has been on naproxen 500mg BID for 4 months with inadequate pain control. Current pain scale 7/10. NDI (Neck Disability Index) score: 52/100 indicating severe disability."

Clinical rationale paragraph: Reference current NASS (North American Spine Society) evidence-based guidelines, which support ACDF for cervical radiculopathy unresponsive to 6+ weeks of conservative care. Note any progressive neurological deficits — weakness, reflex changes, sensory loss — as these can support expedited authorization.

Functional impact: "Patient is unable to continue employment as [occupation] due to upper extremity weakness and pain. Unable to perform overhead activities or sustained neck flexion required for daily tasks."

Prognosis: "Without surgical intervention, patient's neurological deficit is at risk of progression to permanent radiculopathy, with increasing disability and potential for cervical myelopathy requiring more extensive decompression."

Neurosurgery LOMN: Deep Brain Stimulation (DBS) Example

Deep Brain Stimulation (DBS) authorization is among the most documentation-intensive prior auth requests in any specialty. Medicare and commercial payers have detailed CPBs for DBS, and the LOMN must address each criterion explicitly. DBS is approved for Parkinson's disease (G20), essential tremor (G25.0), dystonia (G24.x), and obsessive-compulsive disorder (F42.x) with specific sub-criteria for each indication.

For Parkinson's DBS, CMS and major payers require documentation of: (1) confirmed Parkinson's disease diagnosis with duration (typically 4+ years required), (2) inadequate control with optimal medical therapy — specifically documented trials of levodopa and dopamine agonists with doses, duration, and inadequate response, (3) levodopa responsiveness test result, (4) absence of dementia (MMSE or MoCA score), (5) psychiatric clearance (depression and anxiety must be assessed and stable), and (6) multidisciplinary team review.

The LOMN for DBS must include: the patient's UPDRS (Unified Parkinson's Disease Rating Scale) scores both on and off medication — most payers require at least a 30% improvement in UPDRS Part III during the levodopa challenge, confirming device candidate appropriateness. Without UPDRS data, the LOMN is almost always denied.

Medication trial documentation is the most common DBS denial driver: the LOMN must specify carbidopa/levodopa dose (typically 600–1,200mg/day equivalent required), duration of trial, and documented side effects or inadequate response. A vague statement that "patient has been on levodopa without adequate control" is insufficient. Payers want milligrams, months, and outcome measures.

The psychiatric clearance note from a neuropsychologist or psychiatrist should be included as an addendum — not summarized in the LOMN itself. Payers performing quality review of DBS authorizations frequently request the actual psychiatric evaluation, and having it pre-bundled with the initial submission shortens the authorization timeline by 10–15 days on average.

Vascular Surgery LOMN: EVAR Example

Endovascular Aneurysm Repair (EVAR) for abdominal aortic aneurysm (AAA, ICD-10: I71.4) has specific CMS and commercial payer criteria based on aneurysm size, anatomy, and patient surgical risk. The LOMN must address all three domains to avoid denial.

Aneurysm size criteria: Most payers follow the vascular surgery guideline threshold of 5.5 cm or larger for elective repair in average-risk males, and 5.0 cm for females (due to higher rupture risk at smaller diameters). If the aneurysm is below these thresholds, the LOMN must document the specific reason for earlier repair — rapid expansion (>0.5 cm in 6 months), saccular morphology, or symptomatic aneurysm.

Anatomic suitability: EVAR requires adequate proximal neck anatomy. The LOMN should reference CT aortogram findings: proximal neck length (>15mm preferred), angulation (<60 degrees), and iliac access vessel diameter (>7mm typically required for device delivery). These are the criteria the interventional cardiologist or vascular radiologist will have documented in their imaging interpretation; the LOMN should quote those findings explicitly.

Surgical risk documentation: Commercial payers often require documentation that EVAR is being chosen over open repair because of patient comorbidities making open surgery higher risk. Document the patient's cardiac risk assessment (cardiac stress test or echo results), pulmonary function if COPD is present (FEV1/FVC), renal function (eGFR), and ASA classification assigned by the anesthesia team. This positions EVAR as the medically appropriate approach, not merely the convenient one.

Failed conservative management does not apply to EVAR for AAA at threshold size — the condition itself is the indication. However, document the surveillance history: how long the aneurysm has been followed, prior sizes on serial imaging, and the growth trajectory that has now crossed the intervention threshold. This narrative demonstrates appropriate clinical decision-making and is stronger than simply citing current size.

Oncology LOMN: Biologic and Targeted Therapy Example

Oncology prior authorization for biologic and targeted therapies operates under different logic than surgical authorization. Payers adjudicating oncology biologics review: (1) tumor histology and biomarker status, (2) line of therapy, (3) NCCN guideline alignment, and (4) prior treatment failures. The LOMN must address all four.

Tumor histology and biomarker: The LOMN must specify the exact cancer type with ICD-10 (e.g., C34.11 for primary malignant neoplasm of upper lobe, right bronchus), tumor stage (TNM staging), and relevant biomarker status. For targeted therapies, biomarker confirmation is often a coverage prerequisite: pembrolizumab (Keytruda) for NSCLC requires documented PD-L1 TPS ≥1%, with the lab result included. Osimertinib (Tagrisso) requires EGFR exon 19 or 21 mutation. Missing biomarker documentation causes automatic denial.

Line of therapy: Payers strictly enforce line of therapy requirements. A request for a third-line agent after only one documented prior therapy line will be denied. The LOMN must enumerate each prior treatment line with: drug name, dates, number of cycles, and reason for discontinuation (progression, toxicity, or completion). Do not summarize — list each regimen explicitly.

NCCN alignment: Most commercial payers and CMS require that requested oncology biologics appear in the current NCCN Clinical Practice Guidelines as a Category 1 or 2A recommendation for the specific cancer type, stage, and biomarker profile. Quote the NCCN guideline version and category in the LOMN. NCCN Category 1 recommendations (based on high-level evidence with uniform NCCN consensus) have approval rates 20–30% higher than Category 2B recommendations.

Compassionate use or off-label requests require a significantly more detailed LOMN that includes published clinical trial data, any FDA breakthrough designation, and IRB-approved protocol references. Off-label oncology requests denied by commercial payers are frequently overturned at the external appeal level when strong peer-reviewed evidence is presented.

Common LOMN Mistakes That Cause Denials

Even providers with strong clinical documentation skills make predictable LOMN errors that are 100% preventable with awareness and standardized templates. The following are the most common mistakes identified in denial audit reviews:

1. Generic, template-boilerplate language: A LOMN that reads as if it could apply to any patient — without specific dates, objective measures, imaging findings, and individualized clinical narrative — signals to payer reviewers that the document was generated without genuine clinical engagement. Payer medical directors report that generic LOMNs are the fastest path to denial.

2. Omitting the "without treatment" prognosis: The medical necessity argument depends on demonstrating that denial harms the patient. Providers frequently state why the procedure is appropriate but fail to explicitly state what happens if it is not authorized. The without-treatment prognosis is one of the most compelling elements of a strong LOMN and one of the most commonly omitted.

3. Conservative care documentation without outcome measures: "Patient has tried physical therapy" carries zero weight. "Patient completed 12 sessions of PT over 8 weeks ending [date], with final VAS pain score 7/10 and Oswestry score 54% (severe disability), unchanged from pre-PT baseline" is a medically necessary documentation statement.

4. Wrong ICD-10 code in the LOMN body: The ICD-10 code stated in the LOMN must exactly match the code on the authorization request form. A one-digit discrepancy triggers a mismatch flag in automated payer adjudication systems.

5. Provider signature by a resident or PA when the payer requires the attending: Some payers require the LOMN to be signed by a board-certified specialist, not an advanced practice provider. Review payer credentialing requirements before routing LOMNs for signature.

6. Failure to reference the specific payer CPB: LOMNs that explicitly reference the payer's own clinical criteria document — "Per [Payer] Clinical Policy Bulletin [number], this patient meets criteria X, Y, and Z as documented above" — have measurably higher first-pass approval rates because they demonstrate that the submitting practice is working within the payer's framework.

Building a LOMN Template Library by Specialty

The most effective LOMN improvement initiative a practice can undertake is building a specialty-specific LOMN template library — a set of structured document templates, one per high-authorization-volume procedure or drug, that contain the required sections with prompts for provider-specific clinical data.

A well-built LOMN template does not write the letter for the provider; it scaffolds the structure so the provider can complete the individualized clinical content quickly and completely. The template includes: - Pre-populated section headers aligned to payer CPB criteria - Prompts for specific data elements ("Enter MRI date and finding"; "Enter PT dates and final outcome scores") - Drop-in language for standard guideline citations - ICD-10 code reference for the procedure/drug being requested - Signature block with provider credential fields

Template libraries organized by procedure type — rather than by specialty — are more useful because the same procedure (lumbar fusion) may be performed by neurosurgeons, spine surgeons, and orthopedic surgeons, all of whom benefit from the same authorization template.

Maintenance cadence: Review templates against the top three commercial payer CPBs for that procedure every 6 months. Payer criteria change — coverage for spinal cord stimulators, for example, has been revised multiple times in the past three years — and an outdated LOMN template citing superseded criteria is almost worse than no template at all, because it gives the appearance of addressing payer requirements while actually missing current standards.

clinIQ's Pre-Authorization module includes a growing library of specialty-specific LOMN templates, updated quarterly against major payer CPBs, that your authorization team can populate and submit directly from the platform — cutting LOMN preparation time from 45–60 minutes per letter to under 15 minutes for routine cases.